Eris Lifesciences Ltd
NSE:ERIS
Intrinsic Value
Eris Lifesciences Ltd. engages in the provision of pharmaceutical products. [ Read More ]
The intrinsic value of one
ERIS
stock under the Base Case scenario is
hidden
INR.
Compared to the current market price of 916.1 INR,
Eris Lifesciences Ltd
is
hidden
.
Eris Lifesciences Ltd's market capitalization is 124.6B INR.
ERIS stock price is 916.1 INR.
ERIS stock (887.13 INR) is 3% less than its price (916.1 INR).
ERIS stock price (916.1 INR) is 28% less than its Relative Value (1 273.3 INR). Open Relative Valuation
ERIS has upside potential of 19% compared to the average analyst price target.
Open Wall St Estimates
ERIS earns more than enough operating income (5B INR) to safely cover interest payments on its debt (458m INR).
ERIS's ROIC (Return on Invested Capital) for the past 12 months is positive and is equal to 14%.
ERIS's Revenue has grown by 17% over the past 12 months.
ERIS's ROE (Return on Equity) for the past 12 months is positive and is equal to 17%.
ERIS's ROE (Return on Equity) has decreased in the last 3 years from 25% to 17%.
ERIS's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from 24% to 14%.
ERIS has negative Free Cash Flow for the last twelve months.
ERIS's Revenue has been growing by 16% per year for the last 3 years.
ERIS has positive Net Income for the last twelve months.
ERIS's Revenue is forecast to grow at a rate of 24% per year over the next 3 years.
ERIS has positive three-year average ROIC (Return on Invested Capital): 20%. The company is efficient at using invested capital to generate operating income.
ERIS has positive Operating Income for the last twelve months.
ERIS has positive three-year average ROE (Return on Equity): 22%. The company is efficient at transforming stockholders' equity into net income.
ERIS's short-term assets (10B INR) exceed its short-term liabilties (5B INR).
ERIS has positive Net Debt. This means that the company has more debt (6B INR) than cash and short-term investments (2B INR).
ERIS's long-term assets (39B INR) exceed its long-term liabilties (15B INR).
ERIS has positive Gross Profit for the last twelve months.
ERIS's D/E (Debt to Equity) is very low and is equal to 0.26.
ERIS's Altman Z-Score is very high and is equal to 6.92.
Valuation Backtest
Eris Lifesciences Ltd
Run backtest to discover the historical profit from buying and selling
ERIS
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Realty Income Corp
NYSE:O
|
Real Estate
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
This note will be permanently deleted.
Eris Lifesciences Ltd
Balance Sheet Decomposition
Eris Lifesciences Ltd
| Current Assets | 9.6B |
| Cash & Short-Term Investments | 1.9B |
| Receivables | 3.5B |
| Other Current Assets | 4.2B |
| Non-Current Assets | 29.1B |
| Long-Term Investments | 142.9m |
| PP&E | 4.2B |
| Intangibles | 21.6B |
| Other Non-Current Assets | 3.2B |
| Current Liabilities | 5B |
| Accounts Payable | 1.5B |
| Other Current Liabilities | 3.5B |
| Non-Current Liabilities | 9.7B |
| Long-Term Debt | 6.3B |
| Other Non-Current Liabilities | 3.3B |
Earnings Waterfall
Eris Lifesciences Ltd
|
Revenue
|
18.6B
INR
|
|
Cost of Revenue
|
-3.3B
INR
|
|
Gross Profit
|
15.3B
INR
|
|
Operating Expenses
|
-10.4B
INR
|
|
Operating Income
|
4.8B
INR
|
|
Other Expenses
|
-950.2m
INR
|
|
Net Income
|
3.9B
INR
|
Free Cash Flow Analysis
Eris Lifesciences Ltd
| INR | |
| Free Cash Flow | INR |
ERIS Profitability Score
Profitability Due Diligence
Eris Lifesciences Ltd's profitability score is hidden . The higher the profitability score, the more profitable the company is.
Score
Eris Lifesciences Ltd's profitability score is hidden . The higher the profitability score, the more profitable the company is.
ERIS Solvency Score
Solvency Due Diligence
Eris Lifesciences Ltd's solvency score is hidden . The higher the solvency score, the more solvent the company is.
Score
Eris Lifesciences Ltd's solvency score is hidden . The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ERIS Price Targets Summary
Eris Lifesciences Ltd
According to Wall Street analysts, the average 1-year price target for
ERIS
is 1 091.09 INR
with a low forecast of 939.3 INR and a high forecast of 1 333.5 INR.
Shareholder Return
ERIS Price
Eris Lifesciences Ltd
| Average Annual Return | 9% |
| Standard Deviation of Annual Returns | 20.07% |
| Max Drawdown | -32% |
| Market Capitalization | 124.6B INR |
| Shares Outstanding | 136 047 000 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Eris Lifesciences Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Eris Lifesciences Ltd. engages in the provision of pharmaceutical products. The company is headquartered in Ahmedabad, Gujarat. The company went IPO on 2017-06-29. The Company’s manufacturing plant is located in Guwahati, Assam. Its therapeutic areas include oral diabetes care, cardiac care, pain/analgesics, gynecology, gastrointestinal, central nervous system (CNS), and vitamins, minerals and nutrients (VMN). The firm's brands include Glimisave, Eritel, Renerve, Tendia, Olmin, Rabonik, Tayo, Cyblex, Lnbloc, Remylin, Zomelis, Crevast, Atorsave, Ginkocer and Metital. The Company’s wholly owned subsidiaries include Kinedex Healthcare Private Limited, Aprica Healthcare Limited and Eris Healthcare Private Limited.
Contact
IPO
Employees
Officers
The intrinsic value of one
ERIS
stock under the Base Case scenario is
hidden
INR.
Compared to the current market price of 916.1 INR,
Eris Lifesciences Ltd
is
hidden
.
You don't have any saved screeners yet
